David Denning

From Wikipedia, the free encyclopedia
David W. Denning
NationalityBritish
EducationGuy’s Hospital
Known forFounding president of the Global Action Fund for Fungal Infections
Medical career
ProfessionPhysician
FieldInfectious diseases
Institutions
ResearchFungal infection

David W. Denning is a British retired professor of infectious diseases and global health and medical mycology at Wythenshawe Hospital and the University of Manchester. He is the founding president, executive director and chief executive of the Global Action Fund for Fungal Infections (GAFFI), which focusses on the global impact of fungal disease.

He became the director of the UK's National Aspergillosis Centre in Manchester, which treats people with chronic pulmonary aspergillosis (CPA), and led the group that produced the first guidelines for CPA in 2015. He retired from clinical practice in 2020.

Career[]

David Denning studied medicine at Guy’s Hospital, London, and graduated in 1980.[1] He then trained in internal medicine and infectious diseases in London and Glasgow.[1] Between 1985 and 1987 he had a research post with the Medical Research Council, before a three-year fellowship in diagnostic microbiology and infectious diseases at Stanford University, which he completed in 1990.[1]

He became professor of infectious diseases and global health and medical mycology at Wythenshawe Hospital and the University of Manchester.[1] In 2009 he became the director of the UK's National Aspergillosis Centre in Manchester, which treats people with CPA.[2][3] He is the founding president, executive director and chief executive of the GAFFI, which focusses on the global impact of fungal disease.[1][4] Denning led the group that produced the first guidelines for CPA in 2015.[5] He chairs the editorial board of a website which focusses on aspergillus and he leads an organisation which provides education on fungal diseases.[2] Antifungal medications that he has contributed to research in include itraconazole, voriconazole, amphotericin B, caspofungin, and micafungin.[1] He founded two spinout biotechnology companies.[2] In 2020 he retired from clinical practice.[2]

Selected publications[]

  • Denning, David W. (1998). "Invasive Aspergillosis". Clinical Infectious Diseases. 26 (4): 781–803. doi:10.1086/513943. ISSN 1058-4838. JSTOR 4481476. PMID 9564455.
  • Herbrecht, Raoul; Denning, David W.; Patterson, Thomas F.; Bennett, John E.; Greene, Reginald E.; Oestmann, Jörg-W.; Kern, Winfried V.; Marr, Kieren A.; Ribaud, Patricia; Lortholary, Olivier; Sylvester, Richard; Rubin, Robert H.; Wingard, John R.; Stark, Paul; Durand, Christine; Caillot, Denis; Thiel, Eckhard; Chandrasekar, Pranatharthi H.; Hodges, Michael R.; Schlamm, Haran T.; Troke, Peter F.; De Pauw, Ben (8 August 2002). "Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis". New England Journal of Medicine. 347 (6): 408–415. doi:10.1056/NEJMoa020191. hdl:2066/185528. ISSN 0028-4793. PMID 12167683. (Co-authored)
  • Denning, David W. (4 October 2003). "Echinocandin antifungal drugs". The Lancet. 362 (9390): 1142–1151. doi:10.1016/S0140-6736(03)14472-8. ISSN 0140-6736. PMID 14550704. S2CID 35067894.
  • "Hidden Killers: Human Fungal Infections". Science Translational Medicine. 4 (165): 165rv13. 19 December 2012. doi:10.1126/scitranslmed.3004404. ISSN 1946-6234. PMID 23253612. S2CID 3157271. (Co-authored)

References[]

  1. ^ a b c d e f Khalaj, Vahid (September 2018). "Professor David W. Denning an Extraordinary High Achiever in Clinical and Translational Science". Iranian Biomedical Journal. 22 (5): 290–291. doi:10.29252/ibj.22.5.290. ISSN 1028-852X. PMC 6058189. PMID 29397044.
  2. ^ a b c d "Denning, David". ECMM. Retrieved 22 August 2021.
  3. ^ "Professor David Denning". The British Society for Antimicrobial Chemotherapy. Retrieved 20 August 2021.
  4. ^ "David W. Denning FRCP FRCPath FMedSci - Gaffi | Gaffi - Global Action Fund for Fungal Infections". gaffi.org. Retrieved 21 August 2021.
  5. ^ White, Victoria (23 December 2015). "World's first clinical guidelines for chronic fungal lung infections". European Pharmaceutical review. Retrieved 21 August 2021.
Retrieved from ""